Homogeneous Nuclei Analysis for Genotoxic Mode of Action

The patent combines multiple processing steps (cell lysis, nuclei release, biomarker labeling, and detection) into a single homogeneous assay workflow. Cells are lysed directly in the presence of fluorescently-labeled antibodies, eliminating the need for separate fixation, permeabilization, and washing steps required by traditional methods. This merging maintains measurement precision while dramatically reducing assay complexity and processing time.

The patent applies preliminary action by pre-labeling antibodies with fluorescent markers before use in the assay. This allows the antibodies to be ready for immediate use in the homogeneous assay format, eliminating the need for post-lysis labeling steps and reducing overall processing complexity while maintaining detection accuracy.

The patent merges cell lysis and biomarker detection into a single homogeneous step, allowing hundreds of samples to be processed simultaneously without extensive manual handling. This approach maintains detection accuracy while enabling high-throughput analysis, as samples can be prepared and analyzed in multiwell plate formats without the time-consuming sequential steps of traditional methods.

The homogeneous assay format allows samples to self-process through the lysis and detection steps without requiring extensive manual intervention between steps. The detergent-based lysis automatically releases nuclei and allows antibody access to epitopes in situ, eliminating the need for researchers to perform multiple manual transfer and handling operations, thereby significantly increasing productivity.

The patent combines multiple time-consuming steps (cell lysis, nuclei isolation, antibody incubation, and washing) into a single homogeneous reaction step. This merging maintains assay reliability by preserving the biochemical integrity of the interactions while reducing the total processing time from hours to minutes, as no sequential handling or extended incubation periods are required.

The patent skips the traditional intermediate steps of fixation, permeabilization, and extensive washing by using a detergent-based lysis approach that directly releases nuclei and allows antibody access. This rushing through of intermediate steps maintains detection reliability while dramatically reducing the time lost to sample processing, enabling rapid high-throughput analysis.